Pharma Equity Group Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Christian Tange
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1yr |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
We Think Pharma Equity Group (CPH:PEG) Has A Fair Chunk Of Debt
Dec 06
Here's Why Pharma Equity Group (CPH:PEG) Can Afford Some Debt
Aug 18We Think Pharma Equity Group (CPH:PEG) Has A Fair Chunk Of Debt
Apr 08Is Pharma Equity Group (CPH:PEG) A Risky Investment?
Dec 11Would Pharma Equity Group (CPH:PEG) Be Better Off With Less Debt?
Aug 28Pharma Equity Group (CPH:PEG) Is Making Moderate Use Of Debt
Apr 04CEO
Christian Tange (59 yo)
Mr. Christian Henrik Tange is Chief Executive Officer of Pharma Equity Group A/S from April 1, 2025. Mr. Tange was the Chief Financial Officer of Karolinska Development AB (publ) since March 01, 2014. Mr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | no data | no data | |
| Financial Manager | no data | no data | no data | |
| Chief Medical Officer | 2yrs | no data | no data | |
| Chief Executive Officer of Reponex Pharmaceuticals | 1yr | no data | no data |
Experienced Management: PEG's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | less than a year | no data | 2.12% DKK 2.8m | |
| Chairman of the Board | 3yrs | DKK 350.00k | 0.27% DKK 357.6k | |
| Director | less than a year | no data | 0.30% DKK 391.6k | |
| Independent Director | 3yrs | DKK 175.00k | 1.74% DKK 2.3m | |
| Independent Director | 3yrs | DKK 175.00k | no data | |
| Independent Director | 2.2yrs | DKK 175.00k | no data |
Experienced Board: PEG's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 12:55 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharma Equity Group A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.